Skip to content
Global sound
Scrip Podcasts

Scrip Podcasts

Strategic Intent: Praxis CEO On Unlearning, AI And Launching Two Neuroscience Drugs At Once

· 45 min

Show notes

Praxis Precision Medicines is within weeks of FDA decisions on two potential firsts: relutrigine for SCN2A and SCN8A developmental and epileptic encephalopathies, and ulixacaltamide for essential tremor. In this episode of Strategic Intent, In Vivo senior reporter David Wild talks with Praxis CEO Marcio Souza about the company’s philosophy of “unlearning,” how AI is embedded across the organization, and why he believes neurology is entering its own precision medicine era. Souza also explains how Praxis is preparing to launch two very different products at once, how he led the team through…

Live, last hour: 13,263 songs on 5,968 stations in 136 countries

Discover the world through radio

More ways to discover (7)

Heard something good? Save it, or open it straight away in Spotify.

★ Artist of the week The fastest riser on the radio this week
Your song here? From € 9 per week →
TheReal92HipHopContinue listening